[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100595699":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":27,"locations":34,"responsibleParty":53,"collaborators":19,"id":56,"slug":57,"hasResults":58,"nctId":59,"briefTitle":60,"officialTitle":61,"acronym":19,"eligibilityCriteria":62,"healthyVolunteers":58,"sex":63,"minAge":19,"maxAge":19,"enrollmentInfo":64,"targetDuration":19,"studyType":67,"phases":68,"briefSummary":70,"conditions":71,"keywords":19,"overallStatus":37,"whyStopped":19,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":82},{"fullName":5,"class":6},"Chinese Academy of Medical Sciences, Fuwai Hospital","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Echo guided TAVR","EXPERIMENTAL","Patients received Echocardiography guided TAVR",[13],"Procedure: Echocardiography guided TAVR",[15],{"type":16,"name":17,"description":17,"armGroupLabels":18,"otherNames":19},"PROCEDURE","Echocardiography guided TAVR",[9],null,[21,24],{"name":22,"affiliation":5,"role":23},"Xiangbin Pan, MD","PRINCIPAL_INVESTIGATOR",{"name":25,"affiliation":5,"role":26},"Xu Wang, MD","STUDY_DIRECTOR",[28,32],{"name":22,"role":29,"phone":30,"phoneExt":19,"email":31},"CONTACT","+8688396666","panxiangbin@fuwaihospital.org",{"name":25,"role":29,"phone":33,"phoneExt":19,"email":19},"+86 88396655",[35],{"facility":36,"status":37,"city":38,"state":39,"zip":40,"country":41,"countryCode":42,"cosmosGeoPoint":43,"geoPoint":48,"contacts":49},"Fuwai Hospital","RECRUITING","Beijing","Beijing Municipality","100037","China","CN",{"type":44,"coordinates":45},"Point",[46,47],116.39723,39.9075,{"lat":47,"lon":46},[50],{"name":51,"role":29,"phone":52,"phoneExt":19,"email":31},"Xiangbin Pan","088396666",{"type":23,"investigatorFullName":54,"investigatorTitle":55,"investigatorAffiliation":5,"oldNameTitle":19,"oldOrganization":19},"Pan Xiangbin","Principle Investigator","100595699","transaxillary-tavr-with-solely-echocardiography-guidance-100595699",false,"NCT07035847","Transaxillary TAVR With Solely Echocardiography Guidance","Transaxillary Transcatheter Aortic Valve Replacement With Pure Echocardiography Guidance","Inclusion Criteria:\n\n1. symptomatic severe AS determined by echocardiography and Doppler that requiring aortic valve replacement, defined as: mean gradient ≥40 mmHg, peak aortic velocity ≥4 m\u002Fs, and aortic valve area (AVA) ≤1 cm2 (or an indexed AVA ≤0.6 cm2\u002Fm2)\n2. suitable for Transaxillary TAVR\n\nExclusion Criteria:\n\n1. required hybrid procedures or concomitant interventions on other cardiac malformations\n2. inoperable due to extremely high surgical risk or severe comorbidities\n3. untreated clinically significant (\\>70% obstruction) proximal vessel coronary vascular disease amenable to revascularization\n4. previously undergone aortic valve replacement.","ALL",{"count":65,"type":66},20,"ESTIMATED","INTERVENTIONAL",[69],"NA","This study aims to evaluate the safety and feasibility of performing transaxillary transcatheter aortic valve replacement (TA TAVR) guided solely by echocardiography in patients with severe aortic stenosis (AS).",[72],"Aortic Stenosis","2026-02-26",{"date":75,"type":76},"2026-02-27","ACTUAL",{"date":78,"type":76},"2024-10-01",{"date":80,"type":66},"2026-12-31",{"name":5,"class":6},1]